Literature DB >> 6651932

Enhancement of macrophage invasion of tumors by administration of chemotactic factor-antitumor antibody conjugates.

R Obrist, A L Sandberg.   

Abstract

The numbers of macrophages in peritoneal guinea pig hepatomas were significantly (P less than 0.005) elevated by the intraperitoneal injection of a covalent conjugate of the chemotactic peptide, formylmethionylleucylphenylalanine (fMLP), and IgG reactive with surface antigens on the hepatoma cells. These conjugates, which were previously shown to be chemotactic for guinea pig peritoneal exudate macrophages in vitro, increased the numbers of macrophages in the tumors approximately twofold when injected either in a single dose or in five doses. Although five injections of unconjugated fMLP were nearly as effective as the IgG-fMLP conjugates, free fMLP did not enhance the numbers of macrophages in tumors when injected as a single dose. Unconjugated IgG had no effect. The mean tumor weights were decreased in those groups of guinea pigs which received IgG-fMLP but statistical significance was not achieved due to tumor weight variability in all groups.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6651932     DOI: 10.1016/0008-8749(83)90222-8

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  5 in total

1.  Strategies in antibody therapy of cancer.

Authors:  E J Wawrzynczak; A J Davies
Journal:  Clin Exp Immunol       Date:  1990-11       Impact factor: 4.330

2.  Acute and subacute toxicity of chemotactic conjugates between monoclonal antibody and fMet-Leu-Phe in humans: a phase I clinical trial.

Authors:  R Obrist; J Schmidli; R Müller; H Gallati; J P Obrecht
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

3.  Selective Display of a Chemoattractant Agonist on Cancer Cells Activates the Formyl Peptide Receptor 1 on Immune Cells.

Authors:  Eden L Sikorski; Janessa Wehr; Noel J Ferraro; Sophia M Rizzo; Marcos M Pires; Damien Thévenin
Journal:  Chembiochem       Date:  2022-03-09       Impact factor: 3.461

4.  A nano-innate immune system activator for cancer therapy in a 4T1 tumor-bearing mouse model.

Authors:  Xiang-Yu Liu; Mao-Hua Zhu; Xiao-Yu Wang; Xiao Dong; Hai-Jun Liu; Rui-Yang Li; Shi-Chong Jia; Qin Lu; Mei Zhao; Peng Sun; Hong-Zhuan Chen; Chao Fang
Journal:  J Nanobiotechnology       Date:  2022-01-29       Impact factor: 10.435

5.  Synthetic integrin-binding immune stimulators target cancer cells and prevent tumor formation.

Authors:  Manuel Brehs; André J G Pötgens; Julia Steitz; Karine Thewes; Janett Schwarz; Anne C Conibear; Matthias Bartneck; Frank Tacke; Christian F W Becker
Journal:  Sci Rep       Date:  2017-12-14       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.